IGF1 - insulin like growth factor 1 Gene
Also Known as IGF-IB
Species: Oryctolagus cuniculus
Gene Type: protein coding
Gene ID: 100008668
IGF1 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001082026.1 | NP_001075495.1 | insulin-like growth factor I precursor |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
insulin-like growth factor I |
|
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(5)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-15656 | Ceritinib | Inhibitor | 99.95% | Yes |
| HY-15656A | Ceritinib dihydrochloride | Inhibitor | 99.90% | Yes |
| HY-B0025 | Voglibose | Inhibitor | 98.0% | Unkown |
| HY-15656AR | Ceritinib dihydrochloride (Standard) | Inhibitor | / | Unkown |
| HY-15656R | Ceritinib (Standard) | Inhibitor | 99.72% | Unkown |
Bioactive MoleculesInhibitory Antibodies
(2)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99165 | Teprotumumab | Inhibitor | 99.46% | Unkown |
| HY-P990084 | Veligrotug | 99.25% | Unkown |
Clinical Phase
Bioactive Molecules
(14)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-10191 | Linsitinib | Inhibitor | 99.90% | Phase 3 |
| HY-15494 | Picropodophyllin | 99.85% | Phase 2 | |
| HY-10200 | BMS-754807 | Inhibitor | 99.42% | Phase 2 |
| HY-10199A | Ibutamoren | Agonist | 99.84% | Phase 2 |
| HY-153485 | Cimdelirsen | Inhibitor | / | Phase 2 |
| HY-153485A | Cimdelirsen sodium | Inhibitor | / | Phase 2 |
| HY-19565 | KW-2450 tosylate | / | Phase 2 | |
| HY-B0794B | AZ7550 Mesylate | Inhibitor | 98.70% | Phase 1 |
| HY-B0794 | AZ7550 | Inhibitor | 97.09% | Phase 1 |
| HY-15749 | XL228 | Inhibitor | 99.64% | Phase 1 |
| HY-13326 | ASP3026 | 99.88% | Phase 1 | |
| HY-135749 | BN201 | Activator | 99.89% | Phase 1 |
| HY-B0794A | AZ7550 hydrochloride | Inhibitor | 98.66% | Phase 1 |
| HY-114913 | Fenarimol | Inhibitor | 99.78% | Phase 1 |
Bioactive MoleculesInhibitory Antibodies
(9)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P99294 | Ganitumab | Inhibitor | 96.00% | Phase 3 |
| HY-P99197 | Figitumumab | Inhibitor | ≥99.0% | Phase 3 |
| HY-P99189 | Cixutumumab | Inhibitor | 99.63% | Phase 2 |
| HY-P99274 | Xentuzumab | Antagonist | 99.71% | Phase 2 |
| HY-P99284 | Dalotuzumab | 97.43% | Phase 2 | |
| HY-P99218 | Robatumumab | Inhibitor | 98.00% | Phase 2 |
| HY-P99712 | Lonigutamab | 95.00% | Phase 2 | |
| HY-P99672 | Istiratumab | Inhibitor | 98.45% | Phase 2 |
| HY-P991253 | BIIB022 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(84)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-108477 | TMPyP4 tosylate | Inhibitor | 98.0% | Unkown |
| HY-113402 | Gamma-glutamylcysteine | 98.53% | Unkown | |
| HY-116624 | MAZ51 | 99.96% | Unkown | |
| HY-50866 | NVP-AEW541 | 99.92% | Unkown | |
| HY-W015924 | 2-Hydroxyisobutyric acid | 98.0% | Unkown | |
| HY-10262 | BMS-536924 | 99.83% | Unkown | |
| HY-15609 | AZD-3463 | 99.31% | Unkown | |
| HY-N7922 | Urolithin M5 | Inhibitor | 97.31% | Unkown |
| HY-13203 | NVP-TAE 226 | 99.77% | Unkown | |
| HY-10252 | NVP-ADW742 | 99.30% | Unkown | |
| HY-10253 | AG1024 | 99.50% | Unkown | |
| HY-W074890 | Palmitoylglycine | Modulator | 99.84% | Unkown |
| HY-N0908 | Ginsenoside Rg5 | 99.88% | Unkown | |
| HY-10524 | GSK1904529A | 99.03% | Unkown | |
| HY-N1990 | Gypenoside XLIX | 99.88% | Unkown | |
| HY-113402A | Gamma-glutamylcysteine TFA | 96.68% | Unkown | |
| HY-P5133 | Synstatin (92-119) | Inhibitor | 97.61% | Unkown |
| HY-P3226 | JB-1 | 99.63% | Unkown | |
| HY-19820A | NSC45586 sodium | 98.0% | Unkown | |
| HY-100349 | SU4312 | Inhibitor | 99.74% | Unkown |
| HY-135436 | AG 538 | Inhibitor | 98.99% | Unkown |
| HY-P5438 | Srctide | Substrate | 99.71% | Unkown |
| HY-135680 | I-OMe-Tyrphostin AG 538 | Inhibitor | 98.03% | Unkown |
| HY-18785 | Indirubin Derivative E804 | Inhibitor | 98.54% | Unkown |
| HY-P10044 | IGF1Rtide | 99.53% | Unkown | |
| HY-W112938 | TMPyP tetrachloride | Inhibitor | 98.30% | Unkown |
| HY-113402R | Gamma-glutamylcysteine (Standard) | 98.14% | Unkown | |
| HY-130687A | Psicose | 99.90% | Unkown | |
| HY-139783 | 3-Campholenyl-2-butanol | Inducer | 98.0% | Unkown |
| HY-145110 | IGF-1R inhibitor-2 | Inhibitor | 98.36% | Unkown |
| HY-P2090A | Angiopeptin TFA | 99.01% | Unkown | |
| HY-RS06614 | IGF1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-156914 | IGF-1R/SRC-IN-1 | Inhibitor | 99.86% | Unkown |
| HY-125102 | AZ12253801 | Inhibitor | / | Unkown |
| HY-135562 | Ascofuranone | Inhibitor | 96% | Unkown |
| HY-15656S | Ceritinib-d7 | Inhibitor | 98.00% | Unkown |
| HY-177760 | PrCP-7414 | / | Unkown | |
| HY-15494R | Picropodophyllin (Standard) | 99.70% | Unkown | |
| HY-174655 | Human IGF1 mRNA | / | Unkown | |
| HY-21291 | SU-4313 | Modulator | 99.31% | Unkown |
| HY-B0794S | AZ7550-d5 | Inhibitor | / | Unkown |
| HY-N6611 | Chimaphilin | Inhibitor | 99.80% | Unkown |
| HY-50866B | NVP-AEW541 dihydrochloride | / | Unkown | |
| HY-100038 | AZD9362 | Inhibitor | / | Unkown |
| HY-10252A | cis-NVP-ADW742 | Inhibitor | / | Unkown |
| HY-10438 | BMS-577098 | Inhibitor | / | Unkown |
| HY-108230 | ALK-IN-12 | Inhibitor | / | Unkown |
| HY-118046 | GSK2163632A | Inhibitor | / | Unkown |
| HY-13312A | GTx-134 | / | Unkown | |
| HY-15494S | Picropodophyllin-d3 | / | Unkown | |
| HY-15494S1 | Picropodophyllin-d6 | / | Unkown | |
| HY-15656B | Ceritinib mesylate | Inhibitor | / | Unkown |
| HY-162506 | IGF-1R inhibitor-3 | Inhibitor | / | Unkown |
| HY-167854 | KW-2450 free base | Inhibitor | / | Unkown |
| HY-169572 | IGF-1R inhibitor-5 | Inhibitor | / | Unkown |
| HY-169600 | IGF-1R inhibitor-4 | Inhibitor | / | Unkown |
| HY-17603A | (E)-Belizatinib | Inhibitor | / | Unkown |
| HY-177622 | Cibrigirsen | Inhibitor | / | Unkown |
| HY-177622A | Cibrigirsen sodium | Inhibitor | / | Unkown |
| HY-178460 | BRK/PTK6-IN-1 | Inhibitor | / | Unkown |
| HY-179732 | PROTAC ALK degrader-4 | / | Unkown | |
| HY-180972 | PROTAC EML4-ALK Degrader-2 | Inhibitor | / | Unkown |
| HY-182264 | Masoprocol tetrapivalate | Inhibitor | / | Unkown |
| HY-402309 | IGF-1R modulator 1 | Modulator | / | Unkown |
| HY-E70730 | INSR Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-P11431 | Cyclo(Gly-Pro) | / | Unkown | |
| HY-P2090 | Angiopeptin | / | Unkown | |
| HY-RS06615 | IGF1R Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06616 | Igf1r Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06617 | Igf1r Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-100349A | cis-SU4312 | Inhibitor | / | Unkown |
| HY-113402AR | Gamma-glutamylcysteine TFA (Standard) | / | Unkown | |
| HY-113402B | Gamma-glutamylcysteine ammonium | / | Unkown | |
| HY-117885 | PF-5177624 | Inhibitor | / | Unkown |
| HY-119112A | LY 379196 | Inhibitor | / | Unkown |
| HY-138257A | (R)-Indeloxazine benzenesulfonate | Inhibitor | / | Unkown |
| HY-14357 | BMS 695735 | Inhibitor | / | Unkown |
| HY-168616 | CL-A3-7 | Inhibitor | / | Unkown |
| HY-174654 | Human IGF1R mRNA | / | Unkown | |
| HY-174721 | Human EGFR mRNA | / | Unkown | |
| HY-180210 | Ghrelin receptor full agonist-3 | Agonist | / | Unkown |
| HY-RS16528 | Igf1 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS22959 | Igf1 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W749516 | Voglibose-13C3 | Inhibitor | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(4)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P991042 | Anti-IGFBP2 Antibody (M14) | Antagonist | ≥99.0% | Unkown |
| HY-P991134 | Elegrobart | Inhibitor | 95.27% | Unkown |
| HY-P990966 | Redalsomatropin alfa | / | Unkown | |
| HY-P991255 | VRDN-002 | Inhibitor | / | Unkown |